Last updated on November 2018

Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies

Brief description of study

The primary objective of this study is to characterize the safety, tolerability and maximum tolerated dose of BMS-986016 administered alone or in combination with Nivolumab to subjects with relapsed hematologic malignancies. Co-primary objective is to investigate the preliminary efficacy of BMS-986016 in combination with nivolumab in subjects with relapsed or refractory Hodgkin lymphoma (HL), and relapsed or refractory Diffuse Large B Cell lymphoma (DLBCL)

Clinical Study Identifier: NCT02061761

Find a site near you

Start Over

Washington University School Of Medicine

Saint Louis, MO United States
  Connect »